One-hundred-fourteen patients who received surgical removal and KRAS oncogene evaluation of a primary CRC between 2015 and 2018 accepted to reassess KRAS mutational status through liquid biopsy before starting the first-line chemotherapy for the occurrence of distant and non-resectable metastases. This evidence concerns the gene KRAS and colorectal carcinoma.